Cogito Capital Partners

Cogito invests at the early-growth stage in European technology companies with proven business models and global expansion potential. The firm focuses on enterprise software, fintech, and healthtech, operating from Warsaw and New York to bridge European scale-ups into the US market. Operating as a private equity investor rather than a venture capital firm, Cogito targets a concentrated portfolio where transatlantic operational support can directly influence revenue growth.

Cogito targets early-growth companies — businesses that have established product-market fit, strong market traction, and are ready for the next phase of exponential international growth. The firm does not invest in pre-revenue or early-stage venture rounds. Portfolio company stage tags on the firm's website confirm a focus on the 'Growth' stage, with a smaller number of 'Early' stage positions.

With teams in Warsaw and New York, Cogito provides strategic guidance, a robust network, and hands-on operational support for scaling globally. Its model relies on being physically present in the US to help European portfolio companies hire executive talent, win North American enterprise customers, and navigate local go-to-market dynamics. The firm's materials explicitly frame its contribution as extending beyond capital.

The firm's public portfolio and stated sector expertise point to a deliberate concentration in enterprise software, fintech, and healthtech. Sectors such as consumer technology, biotech, deep tech, and climate hardware have no representation in the disclosed portfolio. Cogito functions as a sector-specialist growth equity firm rather than a generalist.

The firm's publicly visible deal structure has not disclosed a formal club-deal or co-investment program. Portfolio companies like Allica Bank and Nomagic raised capital in rounds that attracted other institutional investors, but Cogito has not publicly detailed co-investment arrangements or a syndication model.